A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer

The purpose of this study is to find out how many people with HER2-amplified or HER2-mutated non-small cell lung cancer (NSCLC) experience a decrease in tumor viability when they receive trastuzumab deruxtecan before routine surgery to remove tumors.

Trial Details

NCT ID
NCT07428044
Phase
PHASE2
Sponsor
Memorial Sloan Kettering Cancer Center
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Trastuzumab Deruxtecan
Locations (sample)
  • Ann Arbor, Michigan, United States|42.27756,-83.74088
  • Rochester, Minnesota, United States|44.02163,-92.4699
  • Basking Ridge, New Jersey, United States|40.70621,-74.54932
  • Middletown, New Jersey, United States|40.39428,-74.11709
  • Montvale, New Jersey, United States|41.04676,-74.02292

Key Eligibility Criteria

  • Patients must meet the following criteria for study entry:
  • Neoadjuvant Therapy
  • Signed informed consent form
  • Age ≥18 years

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →